Kintor Pharmaceutical Company Description
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in researching, developing, and commercializing therapeutic drugs for dermatology and tumors indications with the unmet medical needs in the People’s Republic of China.
Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia and acne vulgaris, which is in phase III clinical trial.
The company is developing GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer; GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC); and ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours.
Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People’s Republic of China.
| Country | Cayman Islands |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 168 |
| CEO | Youzhi Tong |
Contact Details
Address: Suzhou Industrial Park Suzhou, 215123 China | |
| Phone | 86 51 2626 39909 |
| Website | kintor.com.cn |
Stock Details
| Ticker Symbol | KNTPF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG5273B1077 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Youzhi Tong | Founder, Chief Executive Officer and Executive Chairman |
| Dr. Xiang Ni | Chief Medical Officer and Executive Director |
| Ming Ming Cheung | Joint Company Secretary and Chief Financial Officer |
| Wai Chiu Wong C.P.A., CTP, FCS | Company Secretary |